Obesity evidence dossier
VK2735
The unusually early magnitude is notable, but the 13-week duration and dose escalation make it hard to compare directly with 48- to 72-week datasets. Now in Phase 3, so longer-duration confirmatory data are pending.
Total weight loss
14.7%
VENTURE · 15 mg weekly · week 13 · Analysis not fully specified
Placebo-adjusted
13.1%
Difference from placebo in the same study when reported.
Study context
GLP-1/GIP receptor agonist/Adults with obesity or overweight, without diabetes/176 participants across the study/13-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
VENTURE · 15 mg weekly · 13 weeks
Adults with obesity or overweight, without diabetes. 176 participants across the study (not this dose arm alone).
Analysis not fully specified. The source does not establish a treatment-policy analysis; interpret this score provisionally. Reported least-squares means; published adjusted difference retained despite rounded arm means.
- Average weight loss
- 14.7%
- Placebo group
- 1.7% loss
- Beyond placebo
- 13.1 percentage points (published difference)
- Stopped due to adverse events
- Not verified for this result
Only 13 weeks of treatment, including dose escalation.
Score: 70% × 60.7 total-loss points + 30% × 63.6 beyond-placebo points = 62/100, rounded. Conversion scales
Viking, VENTURE results ↗Phase 2 · Sponsor disclosure · Reviewed 2026-09-21
Evidence
Benchmark read
VENTURE: Analysis not fully specified. Reported least-squares means; published adjusted difference retained despite rounded arm means. Only 13 weeks of treatment, including dose escalation.
Diabetes data
Diabetes cohorts should be signposted separately once available.
Safety
Side effects and cautions
Discontinuation read
Adverse-event discontinuation has not been verified for this result.
Common side effects
Gastrointestinal adverse events are the main class-linked tolerability consideration.
Main cautions
Not approved; the VENTURE efficacy figure is a 13-week Phase 2 result, and longer-duration Phase 3 VANQUISH data are needed before ranking it against approved medicines.
Upcoming catalyst
What to watch next
Phase 3 VANQUISH readouts and oral formulation data.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT07104500
Phase 3
VK2735 for Weight Management Phase 3
Viking Therapeutics, Inc.
Non-diabetic obesity
Nov 24, 2025
NCT06828055
Phase 2
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
Viking Therapeutics, Inc.
Non-diabetic obesity
Oct 6, 2025
NCT06068946
Phase 2
VK2735 for Weight Management Phase 2
Viking Therapeutics, Inc.
Non-diabetic obesity
Feb 12, 2025
NCT07104383
Phase 3
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Viking Therapeutics, Inc.
Type 2 diabetes / obesity
Feb 13, 2026